comprehensive -WSS

comprehensive

author：comprehensive 2025-09-28 03:33:05 Page View：5

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical mystery: When an infection after surgery isn’t what it seems
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

knowledge

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Adults seen as increasingly susceptible to measles

MikeReddyforSTATSimonMatthewsmadethreetripsthisspringtotheemergencyroomofhislocalhospitalinEastbourn

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

4:15FormerPresidentDonaldTrumpspeaksbeforeheboardshisplaneatRonaldReaganWashingtonNationalAirport,Au

comprehensive

explore

knowledge

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date